Global In Silico Clinical Trials Market, By Industry (Medical Devices v/s Pharmaceuticals), By Therapeutic Area (Oncology, Neurology, Cardiology, Infectious Diseases, Orthopedic, Dermatology, Others), By Region, Competition Forecast and Opportunities, 2027

January 2022 | 177 pages | ID: GAE28F1C4DA0EN
TechSci Research

Abstracts

Global in silico clinical trials market was valued to be USD2743.64 million in the year 2021 and is expected to grow with a CAGR of 12.28% in the forecast period, 2023-2027 to reach a market value of USD5451.19 million by 2027F. The market is anticipated to grow on the account of growing demand for clinical trials that are cost-effective, time-efficient, and avoids animal cruelty. In-silico clinical trials satisfy these demands. Moreover, Increasing instances of communicable and non-communicable diseases like cancer, diabetes, cardiovascular diseases, neurological disorders, SARS-CoV-2, among others are further driving the growth of the global in silico clinical trials market in the upcoming five years. Also, growing pharma industry and increased development of the innovative pharmaceutical products as treatment for the growing instances of the diseases is also supporting the growth of the global in silico clinical trials market in the next five years. Technological advancements to enhance the rate of successful clinical trials by using computational tools, software and platforms that would support the drug discoveries and latest medical equipment and tools launch is expected to further substantiate the growth of the global in silico clinical trials market in the future five years.

SARS-CoV-2 virus spread during the year 2020 continued its effect in 2021 and is still spreading. The pandemic has affected the healthcare industry on multiple sections. During the crisis, Universal Immune System Simulator (UISS) which is an in-silico clinical trials platform, was utilized to understand the functions, spread, and lifecycle of the virus. The platform also aided the process of design effective vaccines based on monoclonal antibodies and for predicting the outcome of vaccination strategy against SARS-CoV-2.

The global in silico clinical trials market segmentation is based on industry, therapeutic area, regional distribution and competitional landscape. Based on industry, the market is further bifurcated into medical devices and pharmaceuticals. Medical devices are anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years on the account of increasing technological advancement and demands for the more effective and efficient medical devices for the early diagnostics and effective treatments for the growing instances of diseases. Increasing investment in the manufacturing of these devices and designing is also supporting the growth of the sub-segment. Pharmaceuticals are expected to register fastest growing CAGR value in the next five years on the grounds of increasing drug discoveries, expanding pharma industry, and growing governmental financial supports.

Dassault Syst?mes SE, Certara Inc., Insilico Medicine, GNS Healthcare Inc., The AnyLogic Company, Novadiscovery SAS, InSilicoTrials Technologies SpA, Immunetrics Inc, CATO SMS, Evotec SE are some of the major players operating in the global in silico clinical trials market.

Years considered for this report:

• Historical Years: 2017-2020
• Base Year: 2021
• Estimated Year: 2022E
• Forecast Period: 2023F–2027F

Objective of the Study:

• To analyze the market size of global in silico clinical trials market from 2017 to 2021.
• To estimate and forecast the market size of global in silico clinical trials market from 2022E to 2027F and growth rate until 2027F.
• To classify and forecast global in silico clinical trials market based on industry, therapeutic area, regional distribution and competitional landscape.
• To identify dominant region or segment in the global in silico clinical trials market.
• To identify drivers and challenges for global in silico clinical trials market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global in silico clinical trials market.
• To identify and analyze the profile of leading players operating in global in silico clinical trials market.
• To identify key sustainable strategies adopted by market players in global in silico clinical trials market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of service providers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the service providers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the service providers, and presence of all major players across the globe.

TechSci Research calculated the market size of global in silico clinical trials market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

• Suppliers, distributors and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to in silico clinical trials
• Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as service provider, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global in silico clinical trials market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• In Silico Clinical Trials Market, By Industry:
• Medical Devices
• Pharmaceuticals
• In Silico Clinical Trials Market, By Therapeutic Area:
• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Orthopedic
• Dermatology
• Others
• In Silico Clinical Trials Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• Asia Pacific
• Japan
• China
• Australia
• India
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global in silico clinical trials market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

2. RESEARCH METHODOLOGY

3. IMPACT OF COVID-19 ON GLOBAL IN SILICO CLINICAL TRIALS MARKET

4. EXECUTIVE SUMMARY

5. VOICE OF CUSTOMER

5.1. Brand Awareness
5.2. Factors Contributing to Switch to In Silico Clinical Trials
5.3. Demand for In Silico Clinical Trials, By Therapeutic Area
5.4. Preference for In Silico Clinical Trials, By Industry

6. GLOBAL IN SILICO CLINICAL TRIALS MARKET OUTLOOK, 2017-2027F

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Industry (Medical Devices v/s Pharmaceuticals)
  6.2.2. By Therapeutic Area (Oncology, Neurology, Cardiology, Infectious Diseases, Orthopedic, Dermatology, Others)
  6.2.3. By Company (2021)
  6.2.4. By Region
6.3. Product Market Map
  6.3.1. By Industry
  6.3.2. By Therapeutic Area
  6.3.3. By Region

7. NORTH AMERICA IN SILICO CLINICAL TRIALS MARKET OUTLOOK, 2017-2027F

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Industry
  7.2.2. By Therapeutic Area
  7.2.3. By Country
7.3. North America: Country Analysis
  7.3.1. United States In Silico Clinical Trials Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Industry
      7.3.1.2.2. By Therapeutic Area
  7.3.2. Canada In Silico Clinical Trials Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Industry
      7.3.2.2.2. By Therapeutic Area
  7.3.3. Mexico In Silico Clinical Trials Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Industry
      7.3.3.2.2. By Therapeutic Area

8. EUROPE IN SILICO CLINICAL TRIALS MARKET OUTLOOK, 2017-2027F

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Industry
  8.2.2. By Therapeutic Area
  8.2.3. By Country
8.3. Europe: Country Analysis
  8.3.1. France In Silico Clinical Trials Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Industry
      8.3.1.2.2. By Therapeutic Area
  8.3.2. Germany In Silico Clinical Trials Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Industry
      8.3.2.2.2. By Therapeutic Area
  8.3.3. United Kingdom In Silico Clinical Trials Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Industry
      8.3.3.2.2. By Therapeutic Area
  8.3.4. Italy In Silico Clinical Trials Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Industry
      8.3.4.2.2. By Therapeutic Area
  8.3.5. Spain In Silico Clinical Trials Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Industry
      8.3.5.2.2. By Therapeutic Area

9. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET OUTLOOK, 2017-2027F

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Industry
  9.2.2. By Therapeutic Area
  9.2.3. By Country
9.3. Asia-Pacific: Country Analysis
  9.3.1. Japan In Silico Clinical Trials Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Industry
      9.3.1.2.2. By Therapeutic Area
  9.3.2. China In Silico Clinical Trials Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Industry
      9.3.2.2.2. By Therapeutic Area
  9.3.3. Australia In Silico Clinical Trials Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Industry
      9.3.3.2.2. By Therapeutic Area
  9.3.4. India In Silico Clinical Trials Market Outlook
    9.3.4.1. Market Size & Forecast
      9.3.4.1.1. By Value
    9.3.4.2. Market Share & Forecast
      9.3.4.2.1. By Industry
      9.3.4.2.2. By Therapeutic Area
  9.3.5. South Korea In Silico Clinical Trials Market Outlook
    9.3.5.1. Market Size & Forecast
      9.3.5.1.1. By Value
    9.3.5.2. Market Share & Forecast
      9.3.5.2.1. By Industry
      9.3.5.2.2. By Therapeutic Area

10. SOUTH AMERICA IN SILICO CLINICAL TRIALS MARKET OUTLOOK, 2017-2027F

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Industry
  10.2.2. By Therapeutic Area
  10.2.3. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil In Silico Clinical Trials Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Industry
      10.3.1.2.2. By Therapeutic Area
  10.3.2. Argentina In Silico Clinical Trials Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Industry
      10.3.2.2.2. By Therapeutic Area
  10.3.3. Colombia In Silico Clinical Trials Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Industry
      10.3.3.2.2. By Therapeutic Area

11. MIDDLE EAST AND AFRICA IN SILICO CLINICAL TRIALS MARKET OUTLOOK, 2017-2027F

11.1. Market Size & Forecast
  11.1.1. By Value
11.2. Market Share & Forecast
  11.2.1. By Industry
  11.2.2. By Therapeutic Area
  11.2.3. By Country
11.3. MEA: Country Analysis
  11.3.1. South Africa In Silico Clinical Trials Market Outlook
    11.3.1.1. Market Size & Forecast
      11.3.1.1.1. By Value
    11.3.1.2. Market Share & Forecast
      11.3.1.2.1. By Industry
      11.3.1.2.2. By Therapeutic Area
  11.3.2. Saudi Arabia In Silico Clinical Trials Market Outlook
    11.3.2.1. Market Size & Forecast
      11.3.2.1.1. By Value
    11.3.2.2. Market Share & Forecast
      11.3.2.2.1. By Industry
      11.3.2.2.2. By Therapeutic Area
  11.3.3. UAE In Silico Clinical Trials Market Outlook
    11.3.3.1. Market Size & Forecast
      11.3.3.1.1. By Value
    11.3.3.2. Market Share & Forecast
      11.3.3.2.1. By Industry
      11.3.3.2.2. By Therapeutic Area

12. MARKET DYNAMICS

12.1. Drivers
12.2. Challenges

13. MARKET TRENDS & DEVELOPMENTS

14. COMPETITIVE LANDSCAPE

14.1. Competition Outlook
14.2. Company Profiles
  14.2.1. Dassault Syst?mes SE
  14.2.2. Certara Inc.
  14.2.3. Insilico Medicine
  14.2.4. GNS Healthcare Inc.
  14.2.5. The AnyLogic Company
  14.2.6. Novadiscovery SAS
  14.2.7. InSilicoTrials Technologies SpA
  14.2.8. Immunetrics Inc
  14.2.9. CATO SMS
  14.2.10. Evotec SE

15. STRATEGIC RECOMMENDATIONS

List Of Figures

LIST OF FIGURES

Figure 1: Global In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 2: Global In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 3: Global In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 4: Global In Silico Clinical Trials Market Share, By Region, By Value, 2017-2027F
Figure 5: Global In Silico Clinical Trials Market Share, By Company, By Value, 2021
Figure 6: Global In Silico Clinical Trials Market Map, By Industry, Market Size (USD Million) & Growth Rate (%), 2021
Figure 7: Global In Silico Clinical Trials Market Map, By Therapeutic Area, Market Size (USD Million) & Growth Rate (%), 2021
Figure 8: Global In Silico Clinical Trials Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021
Figure 9: North America In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 10: North America In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 11: North America In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 12: North America In Silico Clinical Trials Market Share, By Country, By Value, 2017-2027F
Figure 13: United States In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 14: New Cancer Cases Reported in the United States in 2020, Both Sexes, All Ages
Figure 15: United States In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 16: United States In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 17: Canada In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 18: Percentage of Canadians who Reported being Diagnosed with Diabetes, As of 2020, By Age & Gender
Figure 19: Canada In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 20: Canada In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 21: Mexico In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 22: Number of Registered Clinical Studies in Mexico As of February 2021, By Status
Figure 23: Mexico In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 24: Mexico In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 25: Europe In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 26: Europe In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 27: Europe In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 28: Europe In Silico Clinical Trials Market Share, By Country, By Value, 2017-2027F
Figure 29: France In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 30: Percentage of New Cancer Cases in France, Both Sexes, All Ages, 2020
Figure 31: France In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 32: France In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 33: Germany In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 34: Percentage of New Cancer Cases in Germany, Both Sexes, All Ages, 2020
Figure 35: Germany In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 36: Germany In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 37: United Kingdom In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 38: United Kingdom Diabetes Estimates in People of Age Group 20-79 Years (in Thousands)
Figure 39: United Kingdom In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 40: United Kingdom In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 41: Italy In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 42: Number of Individuals Suffering from Diabetes in Italy (In 1,000 People), 2017-2020
Figure 43: Italy In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 44: Italy In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 45: Spain In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 46: Percentage of New Cancer Cases in Spain, By Cancer Site, 2020
Figure 47: Spain In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 48: Spain In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 49: Asia Pacific In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 50: Asia Pacific In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 51: Asia Pacific In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 52: Asia Pacific In Silico Clinical Trials Market Share, By Country, By Value, 2017-2027F
Figure 53: Japan In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 54: Japan Research & Development Expenditure As a Percentage of GDP, 2017-2020
Figure 55: Japan In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 56: Japan In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 57: China In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 58: Percentage of New Cancer Cases in China, Both Sexes, All Ages, 2020
Figure 59: China In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 60: China In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 61: Australia In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 62: Australia Diabetes Estimates in People of Age Group 20-79 Years (in Thousands)
Figure 63: Australia In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 64: Australia In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 65: India In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 66: Number of Cases of Cerebral Stroke in Senior Citizens Across India (In Million)
Figure 67: India In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 68: India In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 69: South Korea In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 70: Percentage of New Cancer Cases in South Korea, Both Sexes, All Ages, 2020
Figure 71: South Korea In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 72: South Korea In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 73: South America In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 74: South America In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 75: South America In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 76: South America In Silico Clinical Trials Market Share, By Country, By Value, 2017-2027F
Figure 77: Brazil In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 78: Brazil Diabetes Estimates in People of Age Group 20-79 Years (In Thousands)
Figure 79: Brazil In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 80: Brazil In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 81: Argentina In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 82: Percentage of New Cancer Cases in South Korea, Both Sexes, All Ages, 2020
Figure 83: Argentina In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 84: Argentina In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 85: Colombia In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 86: Colombia Diabetes Estimates in People of Age Group 20-79 Years (in Thousands)
Figure 87: Colombia In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 88: Colombia In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 89: Middle East & Africa In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 90: Middle East & Africa In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 91: Middle East & Africa In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 92: Middle East & Africa In Silico Clinical Trials Market Share, By Country, By Value, 2017-2027F
Figure 93: South Africa In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 94: Percentage of New Cancer Cases in South Africa, Both Sexes, All Ages, 2020
Figure 95: South Africa In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 96: South Africa In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 97: Saudi Arabia In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 98: Saudi Arabia Diabetes Estimates in People of Age Group 20-79 Years (in Thousands)
Figure 99: Saudi Arabia In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 100: Saudi Arabia In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F
Figure 101: UAE In Silico Clinical Trials Market Size, By Value (USD Million), 2017-2027F
Figure 102: Percentage of New Cancer Cases in UAE, Both Sexes, All Ages, 2020
Figure 103: UAE In Silico Clinical Trials Market Share, By Industry, By Value, 2017-2027F
Figure 104: UAE In Silico Clinical Trials Market Share, By Therapeutic Area, By Value, 2017-2027F